Public Health | May 07, 2026
Experts urge govt. to make 2 mg and 4 mg nicotine replacement therapies more accessible
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Additional data will be presented on a once-weekly oral combination of islatravir and ulonivirine (ISL/ULO) for HIV-1 treatment
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Sales reflect continued strong growth in oncology and vaccines
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
Acute therapies continue to report strong growth compared to chronic ones.
Subscribe To Our Newsletter & Stay Updated
